摘要:
A method of providing a visualization of states of a process includes identifying a set of potential states that can occur during the process and a corresponding set of colors, with each color in the set of colors corresponding to one of the potential states. A fixed ordering is established for the set of colors. A timeline graph including a plurality of colored vertical bars is displayed. Each colored vertical bar corresponds to a time interval of the process and includes at least one color selected from the set of colors based on at least one state occurring during the time interval corresponding to the vertical bar. The plurality of colored vertical bars includes a set of multiple-color vertical bars that each include a plurality of colors appearing in a vertical order based on the fixed ordering.
摘要:
A method of providing a visualization of states of a process includes identifying a set of potential states that can occur during the process and a corresponding set of colors, with each color in the set of colors corresponding to one of the potential states. A fixed ordering is established for the set of colors. A timeline graph including a plurality of colored vertical bars is displayed. Each colored vertical bar corresponds to a time interval of the process and includes at least one color selected from the set of colors based on at least one state occurring during the time interval corresponding to the vertical bar. The plurality of colored vertical bars includes a set of multiple-color vertical bars that each include a plurality of colors appearing in a vertical order based on the fixed ordering.
摘要:
Diazeniumdiolates, wherein the N1 position is substituted by an inorganic or organic moiety and the O2-oxygen is bound to a substituted or unsubstituted aromatic group, are provided. Also provided are O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O2-glycosylated diazeniumdiolates) and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates). The O2-aryl diazeniumdiolates are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions and generate nitric oxide in basic or nucleophilic environments or microenvironments. Also provided are compositions, including pharmaceutical compositions, comprising such compounds and methods of using such compounds.
摘要:
Provided are O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O2-glycosylated diazeniumdiolates) having the formula: in which R is a saccharide, which is attached to the O2 of the compound by the anomeric carbon of a pyranose ring or a furanose ring.
摘要翻译:提供具有下式的O 2 O-糖基化的1-取代的二氮-1-烯-2,2-二醇酯(O 2 O 2 - 糖基化的二氮烯鎓二醇二醇),其中R是 糖类,其通过吡喃糖环或呋喃糖环的异头碳连接到化合物的O 2上。
摘要:
The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I The variables, e.g. A1 to A3, R1 to R4, L1, L2, B1, and B2 are described herein. Compounds and salts of Formula I bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing an HPPK inhibitor of Formula I and methods of treating a bacterial infection in a patient by providing one or more HPPK inhibitors of Formula I to the patient are also provided. Processes and intermediates useful for preparing compounds of Formula I are also provided. Methods of using the disclosed compounds to guide the development of additional novel anti-bacterial agents are also provided.
摘要:
The disclosure provides linked purine pterin compounds and analogs thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I The variables, e.g. A1 to A3, R1 to R4, L1, L2, B1, and B2 are described herein. Compounds and salts of Formula I bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing an HPPK inhibitor of Formula I and methods of treating a bacterial infection in a patient by providing one or more HPPK inhibitors of Formula I to the patient are also provided. Processes and intermediates useful for preparing compounds of Formula I are also provided. Methods of using the disclosed compounds to guide the development of additional novel anti-bacterial agents are also provided.